I serve on the OSOD Executive Board and provide consulting services on many aspects of vision science with a specific focus on nonclinical pharmacology and toxicology study design, data interpretation and data translatability to the clinic. These nonclinical development plans take into consideration regulatory requirements for IND/CTA submissions and further clinical/nonclinical development. In prior industry roles, I have led the ophthalmic nonclinical development efforts regarding the anti-angiogenic molecule of the targeted, and intravitreally administered monoclonal antibody fragment, LucentisTM, a treatment for the neovascular form of age-related macular degeneration and as cofounder of SARcode BioSciences, I led the nonclinical development of Lifitegrast, now XiidraTM , an integrin antagonist for the topical ocular treatment of inflammatory Dry Eye. In therapeutic areas outside of ophthalmology, I have worked across many therapeutic platforms including small molecules, proteins/peptides, oligonucleotides and AAV-based gene therapies treating rare metabolic disorders, oncology indications, neurologic disorders, inflammatory disorders and orthopedic indications. In total I have contributed to the approval of 19 marketed therapeutics.
From experience I have learned that developing therapeutics is never a straight line and includes inevitable and unforeseen challenges. These situations are best navigated with a capable, experienced, and dependable partner. OSOD has a long history of contributing to development programs, with demonstrated success. The OSOD approach puts the patient first and foremost, in delivering safe and effective transformative therapeutics based on translatable nonclinical pharmacology and toxicology data. We assist in delivering this high-quality product in the most time and cost-efficient manner to improve the lives of patients as quickly as possible.
